STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Overview

Regeneron Pharmaceuticals (NASDAQ: REGN) is a renowned American biotechnology company dedicated to inventing, developing, and commercializing transformative medicines for serious diseases. With its headquarters in Westchester County, New York, and a history dating back to 1988, Regeneron has established itself as a trusted innovator in the biopharmaceutical industry by consistently translating cutting‐edge science into life‐changing therapies.

Core Business and Technological Excellence

At the heart of Regeneron’s operations lies a deep commitment to scientific rigor and technological innovation. The company leverages proprietary VelociSuite® technologies, which include the groundbreaking VelocImmune® platform, to generate fully human antibodies and next-generation bispecific antibodies. These advanced techniques enable Regeneron to identify novel targets and rapidly develop therapies across a wide spectrum of indications such as eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic conditions, hematologic disorders, and rare diseases.

Research, Development and Collaborative Approach

Regeneron’s robust R&D engine is fueled by decades of biology expertise and an integrated approach to drug discovery. The company’s research framework harnesses data-powered insights and genetic medicine platforms to drive its clinical research programs. This commitment is reflected in its diverse pipeline of product candidates and regulatory pathways that emphasize both innovation and patient safety. Through strategic partnerships and collaborations with other key industry players, Regeneron further strengthens its technological capacity while expanding its reach in translational medicine.

Market Position and Significance in the Biotechnology Sector

In the competitive landscape of biotech and pharmaceuticals, Regeneron distinguishes itself through its consistent ability to translate scientific discoveries into marketed products. Its portfolio comprises therapies addressing complex diseases by utilizing targeted approaches involving monoclonal antibodies and complementary biologic modalities. The company’s methodical process—from early identification of druggable targets to rigorous clinical testing and eventual commercialization—underscores its expertise, high scientific standards, and commitment to improving patient outcomes.

Operational Strategy and Business Model

Regeneron generates revenue primarily through its commercialization of innovative therapies and strategic collaborations, which amplify its research capabilities. By focusing on conditions with significant unmet medical need, Regeneron positions itself as a dynamic entity capable of addressing diverse therapeutic challenges. Its strategies incorporate efficient drug development processes, collaborative research initiatives, and maintaining robust clinical trial portfolios—all without relying on time-sensitive information or financial forecasts.

E-E-A-T Focus and Investor Considerations

The company’s work is grounded in long-standing scientific expertise and a commitment to ongoing research. By adhering to stringent safety and efficacy protocols and maintaining transparent regulatory communications, Regeneron exemplifies the principles of Expertise, Experience, Authoritativeness, and Trustworthiness (E-E-A-T). For investors and analysts, Regeneron’s approach to innovation, its state-of-the-art proprietary technologies, and its history of successfully translating advanced science into viable therapies present a well-articulated model of modern biotechnology excellence.

Conclusion

Overall, Regeneron Pharmaceuticals represents a compelling example of how rigorous research, technological innovation, and strategic partnerships converge to create transformative medicines. Its consistent emphasis on high-quality science and unbiased, evidence-based development processes not only boosts its market presence but also reinforces its reputation as a trusted biopharmaceutical partner in the global healthcare arena.

  • Decades of scientific expertise
  • Innovative proprietary platforms
  • Diverse therapeutic pipeline
  • Robust R&D and clinical programs
  • Strategic collaborations and transparency
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory multiple myeloma. At a median duration of follow-up of 11 months, an objective response rate of 71% was observed, with 46% achieving a complete response or better. The regimen had a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. All patients treated with 200 mg experienced an adverse event, including 85% who experienced Grade ≥3 adverse events. Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients (12%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) presented encouraging Phase 1 dose-escalation data for REGN5668 (MUC16xCD28) in combination with Libtayo (cemiplimab) at the ESMO IO Congress 2023. Initial results show early clinical activity in patients with recurrent ovarian cancer, with a 21% stable disease rate and a 59% target lesion reduction from baseline in one patient. The combination demonstrated an acceptable safety profile with fatigue, nausea, and pain as the most common treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and webcast on December 14, 2023, to provide an update on its hematology portfolio. This follows data updates presented at the 65th ASH Annual Meeting and Exposition. The webcast can be accessed on the company's website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi's NOTUS trial for Dupixent in patients with COPD with type 2 inflammation showed a 34% reduction in exacerbations, rapid lung function improvement, and plans for a supplemental BLA submission by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to participate in Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. The webcast will be available on the company's website, with a replay and transcript accessible for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period. Established in 1950, Regeneron ISEF gives young scientists a global stage to share their outstanding STEM research and compete for nearly $8 million in awards, prizes, and scholarships. The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition. The increased investment will raise the top ISEF award, the George D. Yancopoulos Innovator Award, to $100,000, the two second place awards, the Regeneron Young Scientist Awards, to $75,000 each, and increase all category awards by 20 percent. Since assuming title sponsorship in 2019, Regeneron ISEF has welcomed over 5,000 high school students representing 64 countries and distributed a total of nearly $22 million in awards, prizes, and scholarships to the top young scientists in the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals will be sharing new and updated data from its hematology pipeline at the American Society of Hematology (ASH) Annual Meeting. The data includes research on six investigational medicines for eight difficult-to-treat blood cancers and disorders. Key presentations will focus on odronextamab in follicular lymphoma and diffuse large B-cell lymphoma, as well as linvoseltamab in multiple myeloma. Odronextamab is currently under regulatory review, and linvoseltamab will present primary endpoint results with longer follow-up.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. reported a 15% increase in revenues to $3.36 billion in the third quarter of 2023. Dupixent global net sales increased by 33% to $3.10 billion, while U.S. net sales for EYLEA and EYLEA HD were $1.49 billion. The company also announced the FDA approval of EYLEA HD for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as the FDA acceptance for priority review of odronextamab for follicular lymphoma and diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. will present long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology annual meeting. The presentations will highlight the durability of visual improvements and consistent safety of EYLEA HD across extended dosing intervals and patient characteristics. Notable presentations include positive two-year results from trials in wet age-related macular degeneration and diabetic macular edema, as well as subgroup data and safety analysis. EYLEA HD is being jointly developed by Regeneron and Bayer AG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals announces positive preliminary results from Phase 1/2 CHORD trial investigating otoferlin gene therapy for children with genetic hearing loss
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $625.6 as of April 2, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 67.6B.

What is the core focus of Regeneron Pharmaceuticals?

Regeneron is a biotechnology company that specializes in discovering, developing, and commercializing innovative medicines for serious diseases using advanced scientific and technological approaches.

Which technologies underpin Regeneron’s research efforts?

The company utilizes its proprietary VelociSuite® and VelocImmune® platforms, which are central to its ability to generate fully human antibodies and next-generation bispecific antibodies.

In which therapeutic areas does Regeneron operate?

Regeneron develops therapies across several areas including eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic and hematologic conditions, as well as rare diseases.

How does Regeneron generate its revenue?

Revenue is primarily generated through the commercialization of approved therapies and strategic collaborations that enhance its research and development capabilities.

What differentiates Regeneron in the competitive biotech landscape?

Its commitment to cutting-edge technology, robust R&D pipeline, and a collaborative approach enable Regeneron to consistently transform scientific discoveries into marketable and efficacious treatments.

How long has Regeneron been active in the biotechnology field?

Regeneron was founded in 1988 and has since built a reputable track record for translating innovative science into transformative therapies.

What are the key elements of Regeneron’s business model?

The model emphasizes rigorous research and development, leveraging proprietary technologies, strategic partnerships, and a focus on addressing unmet medical needs while maintaining high standards of safety and efficacy.

How does Regeneron maintain its E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards?

By consistently investing in advanced research, adhering to strict clinical protocols, engaging transparently with regulatory authorities, and fostering innovations through collaborations, Regeneron demonstrates deep expertise and builds trust in the medical and investment communities.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

67.56B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN